Roxadustat (RXT)(4-hydroxyl-1-methyl-7-phenoxyisoquinoline-3-caboxylic acid)(Fig. 1) is
an orally active prolyl hydroxylase (PHD) inhibitor that increases production of endogenous …

Background: Current studies have limited data on long-term treatment safety and medication
compliance of roxadustat for renal anemia in peritoneal dialysis (PD) patients. We aimed to …

COVID-19, caused by the novel coronavirus SARS-CoV-2, is a global health issue with more
than 2 million fatalities to date. Viral replication is shaped by the cellular microenvironment …

Background: Roxadustat is a new oral drug for anemia in chronic kidney disease (CKD).
This study aimed to synthesize the evidence from randomized controlled trial (RCT)-based …

Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI),
has been used to treat anemia in patients with chronic kidney disease (CKD). However, its …

Background Randomized controlled trials (RCTs) have shown the efficacy and safety of
Roxadustat and conclude that it has the potential to change the treatment for anemia …

Aims Renal anaemia is a common complication of chronic kidney disease (CKD).
Roxadustat is the first‐in‐class oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for …

Background: Chronic kidney disease is a global public health problem, anemia is the most
common complication of chronic kidney disease. Roxadustat is a new drug that can be used …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has created an urgent need
for therapeutics that inhibit the SARS− COV-2 virus and suppress the fulminant inflammation …

Background Anemia is a common complication in chronic kidney disease (CKD) with
increased morbidity and mortality. Recently published RCTs were conducted to compare the …